



Date: June 15, 2020
To: Physicians, Nursing Staff, Laboratory Staff in *Northern Alberta*
From: Special Coagulation Lab, Edmonton, Alberta Precision Laboratories (APL)
Re: Change to Factor V Leiden/APC Resistance Testing Process

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message:

- **Samples collected for Factor V Leiden (FVL) mutation testing will proceed directly to the genetic test. The Activated Protein C Resistance (APCR) screening test will be discontinued on July 1, 2020.**

Why this is important:

- Lavender EDTA will become the only collection tube required. Sodium citrate tubes are no longer required for algorithmic APCR testing collected on or after July 1, 2020.
- The Activated Protein C resistance test will no longer be orderable.
- For results related to FVL mutation status, see the molecular pathology Factor V Leiden result in ConnectCare or in the Pathology folder of Netcare.
- Note: This change impacts the FVL hereditary thrombophilia test only; the factor V (clotting factor) activity assay is unchanged and continues to require a sodium citrate collection. Ensure the correct test is indicated/selected at the time of ordering.

Action Required:

- Be familiar with the ordering, collection requirements, and resulting process for the Factor V Leiden mutation.

Inquiries and feedback may be directed to:

- Dr. E. Turley, Medical Lead for Coagulation, Edmonton, elona.turley@aplabs.ca

This bulletin has been reviewed and approved by:

Dr. Artur Szkotak, Section Chief Hematopathology APL – North Sector